Literature DB >> 3130055

GM1-gangliosidosis: abnormalities in biosynthesis and early processing of beta-galactosidase in fibroblasts.

E Nanba1, A Tsuji, K Omura, Y Suzuki.   

Abstract

Biosynthesis and early processing of beta-galactosidase were analyzed by pulse-chase technique in human fibroblasts. In normal cells, an 84 kDa precursor was processed first to an intermediate form of higher molecular weight (88 kDa), and then to a 64 kDa mature enzyme. This intermediate form was detected also in the culture medium. Biosynthesis of the precursor was apparently normal in four cases of GM1-gangliosidosis, and a precursor of abnormally high molecular weight (86 kDa) was observed in one case. No further processing occurred to the 88 kDa form. It was concluded that the enzyme deficiency was caused by heterogeneous molecular mutations of beta-galactosidase with a defect in early processing in this disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130055     DOI: 10.1016/s0006-291x(88)80108-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

2.  Characterization and purification of human beta-galactosidase overexpressed in recombinant baculovirus-infected Spodoptera frugiperda cells.

Authors:  K Itoh; A Oshima; H Sakuraba; Y Suzuki
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Beta-galactosidase-deficient human fibroblasts: uptake and processing of the exogenous precursor enzyme expressed by stable transformant COS cells.

Authors:  A Oshima; K Itoh; Y Nagao; H Sakuraba; Y Suzuki
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

4.  Primary and secondary elastin-binding protein defect leads to impaired elastogenesis in fibroblasts from GM1-gangliosidosis patients.

Authors:  Anna Caciotti; Maria Alice Donati; Tiziana Bardelli; Alessandra d'Azzo; Graziella Massai; Luciana Luciani; Enrico Zammarchi; Amelia Morrone
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

5.  Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity.

Authors:  Chi-Fan Yang; Jer-Yuarn Wu; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2010-09-30       Impact factor: 8.410

6.  Human beta-galactosidase gene mutations in GM1-gangliosidosis: a common mutation among Japanese adult/chronic cases.

Authors:  K Yoshida; A Oshima; M Shimmoto; Y Fukuhara; H Sakuraba; N Yanagisawa; Y Suzuki
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

7.  Galactosialidosis: molecular heterogeneity in biosynthesis and processing of protective protein for beta-galactosidase.

Authors:  E Nanba; A Tsuji; K Omura; Y Suzuki
Journal:  Hum Genet       Date:  1988-12       Impact factor: 4.132

8.  Protective protein gene mutations in galactosialidosis.

Authors:  M Shimmoto; Y Fukuhara; K Itoh; A Oshima; H Sakuraba; Y Suzuki
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Early proteolytic cleavage with loss of a C-terminal fragment underlies altered processing of the beta-galactosidase precursor in galactosialidosis.

Authors:  Y Okamura-Oho; S Zhang; W Hilson; A Hinek; J W Callahan
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

10.  Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities.

Authors:  Yoshiyuki Suzuki; Seiichiro Ogawa; Yasubumi Sakakibara
Journal:  Perspect Medicin Chem       Date:  2009-05-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.